A new reagent for the induction of T-cell depletion, anti-CD3-CRM9

Journal of Immunotherapy

Volumn 19, Issue 2, 1996, Pages 85-92

  Neville Jr , D M ^a   Scharff, J ^a   Hu, H Z ^a   Rigaut, K ^a   Shiloach, J ^b   Slingerland, W ^c   Jonker, M ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Autoimmune; CD3 ; Immunotoxin; Rhesus; TCR; Transplantation

Indexed keywords

CD3 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GRAFT REJECTION; HISTOINCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SKIN ALLOGRAFT; T LYMPHOCYTE;

EID: 0029935390     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199603000-00001     Document Type: Article

References (37)

1. Anderson RE, Warner NL. Ionizing radiation and the immune response. In: Dixon FJ, Kunkel HG, eds. Advances in immunology. New York: Academic Press, 1976;24:215-67.
2. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994;57:101-15.
3. Hirsch R, Eckhaus M, Auchincloss H Jr, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988;140: 3766-72.
4. Mysliwietz J, Thierfelder S. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient. Blood 1992;80:2661-7.
5. Tian J, Lehmann PV, Kaufman DL. T cell cross-reactivity between Coxsackie virus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med 1979;180:1979-84.
6. Sykes M, Lee LA, Sachs DH. Xenograft tolerance. Immunol Rev 1994;141:245-76.
7. Bach J-F. Immunosuppressive therapy of autoimmune diseases. Immunol Today 1993;14:322-5.
8. Neville DM Jr, Scharff J, Srinivasachar K. In vivo T cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992;89:2585-9.
9. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987;238:536-9.
10. Neville DM Jr, Scharff J, Srinivasachar K. Anti-T cell immunotoxins: a look at post-endocytotic receptor-mediated routing. J Controlled Release 1993;24:133-41.
11. Nooij FJM, Borst JG, Van Meurs GJE, Jonker M, Balner H. Differentiation antigens on rhesus monkey lymphocytes I: identification of T cells bearing CD3 and CD8, and of a subset of CD8-bearing cells. Eur J Immunol 1986;16:975-9.
12. Nooij FJM, Jonker M, Balner H. Differentiation antigens on rhesus monkey lymphocytes II: characterization of RhT3, a CD3-like antigen on T cells. Eur J Immunol 1986;16:981-4.
13. Nooij FM. The polymorphic CD3 differentiation antigen of rhesus monkey lymphocytes, TNO Primate Center (State University Leiden). s-Gravenhage: J. H. Pasmans Offset-drukkerig BU, 1988.
14. Jonker M, Nooij FJM, van Suylichem P, Neuhaus P, Goldstein G. The influence of OKT8F treatment on allograft survival in rhesus monkeys. Transplantation 1986;41:431-5.
15. van Vreeswijk W, Balner H. Major histocompatibility complex matching and other factors influencing skin allograft survival in related and unrelated rhesus monkeys. Transplantation 1980;30:196-202.
16. Esworthy RS, Neville DM Jr. A comparative study of ricin and diphtheria toxin-antibody-conjugate kinetics of protein synthesis inactivation. J Biol Chem 1984;259:11496-504.
17. Pelchen-Matthews A, Armes JE, Griffiths G, Marsh M. Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells. J Exp Med 1991;173:575-87.
18. + mature human T cell populations and clones by human herpes virus. J Immunol 1991;147:685-91.
19. Salmerón A, Sánchez-Madrid F, Ursa MA, Fresno M, Alarcón B. A conformational epitope expressed upon association of CD3-ε with either CD3-δ or CD3-γ is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 1991;147:3047-52.
20. Hu VW, Holmes RK. Single mutation in the A domain of diphtheria toxin results in a protein with altered membrane insertion behavior. Biochim Biophys Acta 1987;902:24-30.
21. Welkos SL, Holmes RK. Regulation of toxinogenesis in Corynebacterium diphtheriae. I. Mutations in bacteriophage β that alter the effects of iron on toxin production. J Virol 1981;37:936-45.
22. Carroll SF, Barbieri JT, Collier RJ. Diphtheria toxin: purification and properties. Methods Enzymol 1988;165:68-76.
23. Neville DM Jr, Srinivasachar K, Stone R, Scharff J. Enhancement of immunotoxin efficacy by acid cleavable crosslinking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem 1989;264:14653-61.
24. Bengtsson M, Totterman TH, Smedmyr B, Festin R, Oberg G, Simonsson B. Regeneration of functional and activated NK and T sub subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3 color FACS analysis. Leukemia 1989; 3:68-75.
25. Thompson J, Hu H, Scharff J, Neville DM Jr. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995;270:28037-41.
26. Gowans JC, Knight EJ. The route of re-circulation of lymphocytes in the rat. Proc R Soc Lond [Biol] 1964;159:257-82.
27. LeMaistre CF, Rosen S, Frankel A, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991;78:1173-82.
28. LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992;79:2547-54.
29. Nooij FJM, Jonker M. The effect on skin allograft survival of a monoclonal antibody specific for a polymorphic CD3-like cell surface molecule in rhesus monkeys. Eur J Immunol 1987;17:1089-93.
30. Parlevliet KJ, Jonker M, Ten Berge RJM, et al. Anti-CD3 murine isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 1990;50:889-92.
31. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41:385-91.
32. Parren PWHI, Geerts MEJ, Boeije LCM, Aarden LA. Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. Res Immunol 1991;142:749-63.
33. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. N Engl J Med 1995;332:143-9.
34. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994;197:1127-35.
35. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993;82:2585-94.
36. Yin D, Fathman CG. CD4-positive suppressor cells block allotransplant rejection. J Immunol 1995;154:6339-45.
37. Tarkowski A, Andersson-Gare B, Aurell M. Use of antithymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol 1993;22: 261-6.